CO2019006183A2 - Nuevas formas de dosificación oral de liberación inmediata y modificada de tebipenem pivoxil - Google Patents
Nuevas formas de dosificación oral de liberación inmediata y modificada de tebipenem pivoxilInfo
- Publication number
- CO2019006183A2 CO2019006183A2 CONC2019/0006183A CO2019006183A CO2019006183A2 CO 2019006183 A2 CO2019006183 A2 CO 2019006183A2 CO 2019006183 A CO2019006183 A CO 2019006183A CO 2019006183 A2 CO2019006183 A2 CO 2019006183A2
- Authority
- CO
- Colombia
- Prior art keywords
- tebipenem pivoxil
- immediate
- dosage forms
- oral dosage
- modified release
- Prior art date
Links
- SNUDIPVBUUXCDG-QHSBEEBCSA-N tebipenem pivoxil Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(=O)OCOC(=O)C(C)(C)C)=O)[C@H](O)C)SC(C1)CN1C1=NCCS1 SNUDIPVBUUXCDG-QHSBEEBCSA-N 0.000 title abstract 4
- 229950007537 tebipenem pivoxil Drugs 0.000 title abstract 3
- 239000006186 oral dosage form Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019206 urinary tract infection Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434643P | 2016-12-15 | 2016-12-15 | |
| US201662438071P | 2016-12-22 | 2016-12-22 | |
| PCT/US2017/066729 WO2018112372A1 (en) | 2016-12-15 | 2017-12-15 | Novel tebipenem pivoxil immediate and modified release oral dosage forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019006183A2 true CO2019006183A2 (es) | 2019-08-30 |
Family
ID=60937949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0006183A CO2019006183A2 (es) | 2016-12-15 | 2019-06-13 | Nuevas formas de dosificación oral de liberación inmediata y modificada de tebipenem pivoxil |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12226403B2 (enExample) |
| EP (2) | EP3554484B1 (enExample) |
| JP (2) | JP7083828B2 (enExample) |
| KR (1) | KR102640532B1 (enExample) |
| CN (2) | CN115192533A (enExample) |
| AU (2) | AU2017377062B2 (enExample) |
| BR (1) | BR112019012171B1 (enExample) |
| CA (1) | CA3045566C (enExample) |
| CO (1) | CO2019006183A2 (enExample) |
| ES (1) | ES3037252T3 (enExample) |
| IL (1) | IL267219B2 (enExample) |
| MX (3) | MX2019007136A (enExample) |
| PH (1) | PH12019501234A1 (enExample) |
| WO (1) | WO2018112372A1 (enExample) |
| ZA (1) | ZA201903309B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115192533A (zh) | 2016-12-15 | 2022-10-18 | 斯派尔治疗有限公司 | 新型替比培南匹伏酯速释和调释口服剂型 |
| JP7309607B2 (ja) | 2017-02-06 | 2023-07-18 | スペロ セラピューティックス，インコーポレイテッド | テビペネムピボキシル臭化水素酸塩の結晶形、および医薬組成物 |
| CN109432044B (zh) * | 2018-11-27 | 2021-05-11 | 山东省药学科学院 | 一种替比培南酯细粒剂及其制备方法 |
| EP4243783A1 (en) * | 2020-11-11 | 2023-09-20 | Spero Therapeutics, Inc. | High dosage tebipenem pivoxil tablet formulation |
| CN115969815A (zh) * | 2023-02-10 | 2023-04-18 | 鲁南贝特制药有限公司 | 一种替比培南酯口服制剂及其制备方法 |
| CN118526466B (zh) * | 2024-07-22 | 2024-11-05 | 山东则正医药技术有限公司 | 一种替比培南匹伏酯颗粒制剂及其制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851230A (en) * | 1983-04-07 | 1989-07-25 | Bristol-Myers Company | Capsule shaped tablets |
| AU682510B2 (en) * | 1993-07-01 | 1997-10-09 | Pfizer Japan Inc. | 2-(1-(1,3-thiazolin-2-yl)azetidin-3-yl)thio-carbapenem derivatives |
| JP3317604B2 (ja) | 1994-12-28 | 2002-08-26 | 日本ワイスレダリー株式会社 | 結晶形態のカルバペネム化合物 |
| TW420681B (en) | 1995-12-08 | 2001-02-01 | Lederle Japan Ltd | Carbapenem-3-carboxylic acid ester derivatives |
| JP2847093B2 (ja) | 1996-03-11 | 1999-01-13 | ソニー株式会社 | ビデオカメラ |
| JP3317649B2 (ja) | 1997-01-13 | 2002-08-26 | 日本ワイスレダリー株式会社 | 結晶形態のカルバペネム化合物 |
| JP2003171277A (ja) | 2001-12-07 | 2003-06-17 | Wyeth Lederle Japan Ltd | 薬物放出時間制御型固形製剤 |
| AU2003211146B2 (en) * | 2002-02-21 | 2007-07-19 | Valeant International (Barbados) Srl | Controlled release dosage forms |
| JP2004035517A (ja) | 2002-07-08 | 2004-02-05 | Wyeth Lederle Japan Ltd | カルバペネム系抗生剤含有経口製剤 |
| JP2004035518A (ja) | 2002-07-08 | 2004-02-05 | Wyeth Lederle Japan Ltd | 苦味をマスキングしたカルバペネム系抗生剤含有経口顆粒製剤 |
| US20060099253A1 (en) * | 2004-10-20 | 2006-05-11 | Wyeth | Antibiotic product formulation |
| WO2007070164A1 (en) * | 2005-10-19 | 2007-06-21 | The Curators Of The University Of Missouri | Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same |
| US20080069879A1 (en) | 2006-05-02 | 2008-03-20 | Ravishekhar Bhiwgade | Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof |
| JP2011504495A (ja) | 2007-11-23 | 2011-02-10 | クジェ ファーマシューティカル インダストリアル カンパニー リミテッド | ２−アリールメチルアゼチジン−カルバペネム−３−カルボン酸エステル誘導体またはその塩、その製造方法及びそれを含む医薬組成物 |
| KR100950699B1 (ko) | 2008-03-28 | 2010-03-31 | 국제약품공업주식회사 | 2-아릴메틸아제티딘-카바페넴-3-카복실산 에스테르유도체의 산부가염, 이의 제조방법 및 이를 포함하는 약학조성물 |
| CN102558181B (zh) * | 2010-12-15 | 2015-04-22 | 石药集团中奇制药技术（石家庄）有限公司 | 一种碳青霉烯抗生素的制备方法 |
| CN102731507B (zh) | 2011-04-13 | 2015-04-01 | 石药集团中奇制药技术（石家庄）有限公司 | 泰比培南晶型、其制备方法及其在制备药物中的应用 |
| CN102276611B (zh) | 2011-05-18 | 2013-01-09 | 深圳万乐药业有限公司 | 一种替比培南酯的重结晶精制方法 |
| CN102860985B (zh) * | 2011-07-06 | 2015-02-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种泰比培南酯口服制剂及其制备方法 |
| CN103371977A (zh) * | 2012-04-25 | 2013-10-30 | 秦引林 | 一种泰比培南酯颗粒及其制备方法 |
| CN102885811B (zh) * | 2012-08-27 | 2014-05-28 | 南京华威医药科技开发有限公司 | 含有泰比培南酯的口服制剂 |
| CN103664948B (zh) | 2012-09-05 | 2015-12-16 | 凌沛学 | 一种替比培南酯的中间体的结晶及其制备方法 |
| CN103664949A (zh) | 2012-09-12 | 2014-03-26 | 高瑞耀业(北京)科技有限公司 | 替比培南匹伏酯结晶及其制备方法 |
| CN102836130A (zh) | 2012-09-19 | 2012-12-26 | 山东罗欣药业股份有限公司 | 一种替比培南匹伏酯颗粒剂 |
| CN103655483A (zh) * | 2012-09-26 | 2014-03-26 | 扬州市星斗药业有限公司 | 一种含有替比培南的颗粒及其制备方法 |
| CN103054815B (zh) * | 2013-02-04 | 2015-12-02 | 南京卡文迪许生物工程技术有限公司 | 替比培南酯口服固体制剂及其制备方法 |
| CN104224725A (zh) | 2013-06-14 | 2014-12-24 | 北京济美堂医药研究有限公司 | 一种替比培南酯颗粒剂及其制备方法 |
| CN104027310B (zh) | 2013-12-26 | 2016-02-03 | 青岛大学 | 一种法罗培南钠颗粒剂及其制备方法 |
| CN104013583B (zh) * | 2014-06-27 | 2019-02-26 | 国药集团致君（深圳）制药有限公司 | 一种泰比培南酯组合物的药物制剂及其制备方法 |
| CN105193742A (zh) | 2015-10-30 | 2015-12-30 | 海口市制药厂有限公司 | 替比培南酯颗粒剂组合物、其制备方法及应用 |
| CN105997891A (zh) * | 2016-05-20 | 2016-10-12 | 郑州明泽医药科技有限公司 | 一种替比培南酯制剂及其制备方法 |
| CN105963261A (zh) * | 2016-07-08 | 2016-09-28 | 河南全宇制药股份有限公司 | 一种替比培南酯颗粒剂及其制备方法 |
| CN115192533A (zh) | 2016-12-15 | 2022-10-18 | 斯派尔治疗有限公司 | 新型替比培南匹伏酯速释和调释口服剂型 |
| JP7309607B2 (ja) | 2017-02-06 | 2023-07-18 | スペロ セラピューティックス，インコーポレイテッド | テビペネムピボキシル臭化水素酸塩の結晶形、および医薬組成物 |
| CN107737107B (zh) | 2017-12-02 | 2020-05-29 | 北京达因高科儿童药物研究院有限公司 | 一种含替比培南酯组合物的口服制剂及其制备方法 |
| EP4243783A1 (en) | 2020-11-11 | 2023-09-20 | Spero Therapeutics, Inc. | High dosage tebipenem pivoxil tablet formulation |
-
2017
- 2017-12-15 CN CN202210913933.4A patent/CN115192533A/zh active Pending
- 2017-12-15 EP EP17826092.3A patent/EP3554484B1/en active Active
- 2017-12-15 US US16/470,058 patent/US12226403B2/en active Active
- 2017-12-15 WO PCT/US2017/066729 patent/WO2018112372A1/en not_active Ceased
- 2017-12-15 CA CA3045566A patent/CA3045566C/en active Active
- 2017-12-15 EP EP22160275.8A patent/EP4032531A1/en active Pending
- 2017-12-15 AU AU2017377062A patent/AU2017377062B2/en active Active
- 2017-12-15 MX MX2019007136A patent/MX2019007136A/es unknown
- 2017-12-15 KR KR1020197019796A patent/KR102640532B1/ko active Active
- 2017-12-15 BR BR112019012171-4A patent/BR112019012171B1/pt active IP Right Grant
- 2017-12-15 IL IL267219A patent/IL267219B2/en unknown
- 2017-12-15 CN CN201780077794.3A patent/CN110072520A/zh active Pending
- 2017-12-15 ES ES17826092T patent/ES3037252T3/es active Active
- 2017-12-15 JP JP2019533101A patent/JP7083828B2/ja active Active
-
2019
- 2019-05-24 ZA ZA2019/03309A patent/ZA201903309B/en unknown
- 2019-06-03 PH PH12019501234A patent/PH12019501234A1/en unknown
- 2019-06-13 CO CONC2019/0006183A patent/CO2019006183A2/es unknown
- 2019-06-14 MX MX2022014095A patent/MX2022014095A/es unknown
- 2019-06-14 MX MX2022006971A patent/MX2022006971A/es unknown
-
2020
- 2020-12-03 AU AU2020281095A patent/AU2020281095B2/en active Active
-
2022
- 2022-06-01 JP JP2022089414A patent/JP7431886B2/ja active Active
-
2024
- 2024-09-18 US US18/888,372 patent/US20250009718A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019006183A2 (es) | Nuevas formas de dosificación oral de liberación inmediata y modificada de tebipenem pivoxil | |
| CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
| CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
| MX2019014514A (es) | Compuestos para tratar la enfermedad de huntington. | |
| BR112019012062A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos | |
| CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
| MX2017015588A (es) | Materiales marcadores y formas para la localización de marcadores magnéticos (mml). | |
| MX383499B (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| CO2018003224A2 (es) | Formulaciones de aminoacidos de liberacion modificada administradas oralmente | |
| MX2015015228A (es) | Sobetirome en el tratamiento de enfermedades de mielinizacion. | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| MX2018015089A (es) | Combinacion de linagliptina y metformina. | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
| CL2019003743A1 (es) | Formas de dosificación oral y de liberación controlada gastrorresistentes. | |
| BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial | |
| MX2018002338A (es) | Sondas para formar imagenes de proteina de huntingtina. | |
| CO2017007874A2 (es) | Composiciones y métodos para metabolismo muscular mejorado | |
| BR112015021480A2 (pt) | soluções de hidromorfona intratecais tendo estabi-lidade melhorada | |
| UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet | |
| MX386393B (es) | Andrografólido para tratar formas progresivas de esclerosis múltiple. | |
| ES2633733T3 (es) | Uso de xenón para prevenir o tratar las consecuencias neurológicas de un choque séptico |